Prothena Corporation plc (NASDAQ:PRTA) went down by -11.04% from its latest closing price compared to the recent 1-year high of $79.75. The company’s stock price has collected -16.23% of loss in the last five trading sessions. Press Release reported on 11/29/21 that Prothena to Participate in JMP Securities Hematology and Oncology Summit
Is It Worth Investing in Prothena Corporation plc (NASDAQ :PRTA) Right Now?
Prothena Corporation plc (NASDAQ:PRTA) scored a price-to-earnings ratio above its average ratio, recording 36.24 x from its present earnings ratio. Plus, the 36-month beta value for PRTA is at 1.24. Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Prothena Corporation plc declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $84.71, which is $44.75 above the current price. PRTA currently public float of 25.13M and currently shorts hold a 9.83% ratio of that float. Today, the average trading volume of PRTA was 377.92K shares.
PRTA’s Market Performance
PRTA stocks went down by -16.23% for the week, with a monthly drop of -15.17% and a quarterly performance of -41.43%, while its annual performance rate touched 175.31%. The volatility ratio for the week stands at 8.84% while the volatility levels for the past 30 days are set at 7.32% for Prothena Corporation plc. The simple moving average for the period of the last 20 days is -17.94% for PRTA stocks with a simple moving average of -23.89% for the last 200 days.
Analysts’ Opinion of PRTA
Many brokerage firms have already submitted their reports for PRTA stocks, with JMP Securities repeating the rating for PRTA by listing it as a “Mkt Outperform.” The predicted price for PRTA in the upcoming period, according to JMP Securities is $77 based on the research report published on November 19th of the previous year 2021.
BofA Securities, on the other hand, stated in their research note that they expect to see PRTA reach a price target of $49, previously predicting the price at $12. The rating they have provided for PRTA stocks is “Neutral” according to the report published on June 18th, 2021.
Oppenheimer gave a rating of “Outperform” to PRTA, setting the target price at $54 in the report published on June 08th of the previous year.
PRTA Trading at -25.15% from the 50-Day Moving Average
After a stumble in the market that brought PRTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.02% of loss for the given period.
Volatility was left at 7.32%, however, over the last 30 days, the volatility rate increased by 8.84%, as shares sank -11.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.79% lower at present.
During the last 5 trading sessions, PRTA fell by -16.23%, which changed the moving average for the period of 200-days by +65.36% in comparison to the 20-day moving average, which settled at $45.43. In addition, Prothena Corporation plc saw -24.15% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at PRTA starting from EcoR1 Capital, LLC, who purchase 300,000 shares at the price of $37.50 back on Jan 12. After this action, EcoR1 Capital, LLC now owns 11,584,280 shares of Prothena Corporation plc, valued at $11,250,300 using the latest closing price.
Selkoe Dennis J., the Director of Prothena Corporation plc, sale 5,000 shares at $47.45 during a trade that took place back on Jan 03, which means that Selkoe Dennis J. is holding 2,845 shares at $237,233 based on the most recent closing price.
Stock Fundamentals for PRTA
Current profitability levels for the company are sitting at:
- -13216.18 for the present operating margin
The net margin for Prothena Corporation plc stands at -13029.78. The total capital return value is set at -45.30, while invested capital returns managed to touch -45.64. Equity return is now at value 23.20, with 15.60 for asset returns.
Based on Prothena Corporation plc (PRTA), the company’s capital structure generated 9.69 points at debt to equity in total, while total debt to capital is 8.84. Total debt to assets is 5.36, with long-term debt to equity ratio resting at 6.70. Finally, the long-term debt to capital ratio is 6.11.
When we switch over and look at the enterprise to sales, we see a ratio of 8.43, with the company’s debt to enterprise value settled at 0.09. The receivables turnover for the company is 20.55 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.58.